Artiva Biotherapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 10, 2026
ARTV$4.22+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
(in thousands, except share and par value data)
| AS OF | ||
|---|---|---|
| DECEMBER 31,2025 | DECEMBER 31,2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $26,701 | $40,235 |
| Short-term investments | 81,307 | 145,193 |
| Other receivables (including related party amounts of $61 and $0, respectively) | 67 | 146 |
| Prepaid expenses and other current assets | 4,591 | 3,057 |
| Total current assets | 112,666 | 188,631 |
| Restricted cash | 461 | 258 |
| Property and equipment, net | 6,618 | 6,370 |
| Operating lease right-of-use assets | 10,525 | 13,794 |
| Financing lease right-of-use asset | 212 | 261 |
| Other long-term assets | 458 | 267 |
| Total assets | $130,940 | $209,581 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable (including related party amounts of $0 and $276, respectively) | $355 | $1,121 |
| Accrued expenses (including related party amounts of $0 and $713, respectively) | 9,600 | 7,392 |
| Current portion of operating lease liabilities | 3,015 | 3,618 |
| Current portion of financing lease liability | 44 | 122 |
| Other current liabilities | 73 | — |
| Total current liabilities | 13,087 | 12,253 |
| Operating lease liabilities, net of current portion | 7,883 | 10,570 |
| Financing lease liability, net of current portion | — | 44 |
| Other non-current liabilities | — | 73 |
| Total liabilities | 20,970 | 22,940 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2025 and December 31, 2024; zero shares issued and outstanding as of December 31, 2025 and December 31, 2024 | — | — |
| Common stock, $0.0001 par value; 700,000,000 shares authorized at December 31, 2025 and December 31, 2024; 24,595,550 and 24,291,607 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 3 | 3 |
| Additional paid-in capital | 440,413 | 433,451 |
| Accumulated other comprehensive income (loss) | 103 | (129) |
| Accumulated deficit | (330,549) | (246,684) |
| Total stockholders’ equity | 109,970 | 186,641 |
| Total liabilities and stockholders’ equity | $130,940 | $209,581 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.